

References

This is the reference list to the ACE Clinical Guideline “Major depressive disorder – achieving and sustaining remission”.

1. Abdin E, Chong SA, Vaingankar JA, et al. Impact of mental disorders and chronic physical conditions on quality-adjusted life years in Singapore. *Sci Rep*. 2020;10(1):2695.
2. Bains N, Abdijadid S. Major depressive disorder: StatPearls Publishing. 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559078/> [Accessed 3 March 2025].
3. Marwaha S, Palmer E, Suppes T, et al. Novel and emerging treatments for major depression. *Lancet*. 2023;401(10371):141-153.
4. World Health Organization. International Classification of Diseases, Eleventh Revision (ICD-11). 2024. Available from: <https://icd.who.int/browse/2024-01/mms/en> [Accessed 3 March 2025].
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition, text revision. Washington, DC, American Psychiatric Association. 2022.
6. Chodavadia P, Teo I, Poremski D, et al. Prevalence and economic burden of depression and anxiety symptoms among Singaporean adults: results from a 2022 web panel. *BMC Psychiatry*. 2023;23(1):104.
7. Ganesh KK, Abdin E, Vaingankar JA, et al. The relationship between suicidality and socio-demographic variables, physical disorders, and psychiatric disorders: results from the Singapore Mental Health Study 2016. *Int J Environ Res Public Health*. 2021;18(8):4365.
8. The Interagency Taskforce on Mental Health and Well-being. National mental health and well-being strategy. Singapore. 2023.
9. Chua YCE, Lin YC, Lew JK, et al. Prevalence and risk factors of depression and anxiety in primary care. *Ann Acad Med Singap*. 2024;53(5):293-305.
10. Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. *Can J Psychiatry*. 2024;69(9):641-687.
11. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry*. 2006;163(11):1905-1917.
12. Yeung AS, Jing Y, Brennenman SK, et al. Clinical Outcomes in Measurement-based Treatment (Comet): a trial of depression monitoring and feedback to primary care physicians. *Depress Anxiety*. 2012;29(10):865-873.
13. Zhou D, Zhou X, Lin Q, et al. Nonpharmacological interventions for relapse prevention in unipolar depression: A network meta-analysis. *J Affect Disord*. 2021;282:1255-1262.
14. Zhou D, Lv Z, Shi L, et al. Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves. *Psychol Med*. 2022;52(1):48-56.
15. Krijnen-de Bruin E, Scholten W, Muntingh A, et al. Psychological interventions to prevent relapse in anxiety and depression: A systematic review and meta-analysis. *PLoS One*. 2022;17(8):e0272200.
16. Department of Veterans Affairs and Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of major depressive disorder. Washington, DC: U.S. Government Printing Office. 2022.
17. Qaseem A, Owens DK, Etzeandía-Ikobaltzeta I, et al. Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians. *Ann Intern Med*. 2023;176(2):239-252.
18. Malaysian Health Technology Assessment Section (MaHTAS). Management of major depressive disorder (second edition). 2019. Available from: <https://www.moh.gov.my/index.php/pages/view/3962> [Accessed 3 March 2025].
19. National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management (NICE guideline NG222). 2022. Available from: <https://www.nice.org.uk/guidance/ng222> [Accessed 3 March 2025].

20. Ghio L, Gotelli S, Marcenaro M, et al. Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. *J Affect Disord.* 2014;152-154:45-51.
21. Department of Veterans Affairs and Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the assessment and management of patients at risk for suicide. Washington, DC: U.S. Government Printing Office. 2019.
22. Li X, Mu F, Liu D, et al. Predictors of suicidal ideation, suicide attempt and suicide death among people with major depressive disorder: A systematic review and meta-analysis of cohort studies. *J Affect Disord.* 2022;302:332-351.
23. Koh YS, Shahwan S, Jeyagurunathan A, et al. Prevalence and correlates of suicide planning and attempt among individuals with suicidal ideation: Results from a nationwide cross-sectional survey. *J Affect Disord.* 2023;328:87-94.
24. Franklin JC, Ribeiro JD, Fox KR, et al. Risk factors for suicidal thoughts and behaviors: A meta-analysis of 50 years of research. *Psychol Bull.* 2017;143(2):187-232.
25. Amore M, Menchetti M, Tonti C, et al. Predictors of violent behavior among acute psychiatric patients: clinical study. *Psychiatry Clin Neurosci.* 2008;62(3):247-255.
26. Furukawa TA, Shinohara K, Sahker E, et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. *World Psychiatry.* 2021;20(3):387-396.
27. Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. *World Psychiatry.* 2020;19(1):92-107.
28. Gartlehner G, Dobrescu A, Chapman A, et al. Nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians. *Ann Intern Med.* 2023;176(2):196-211.
29. Cuijpers P, Oud M, Karyotaki E, et al. Psychologic treatment of depression compared with pharmacotherapy and combined treatment in primary care: a network meta-analysis. *Ann Fam Med.* 2021;19(3):262-270.
30. Cuijpers P, Miguel C, Ciharova M, et al. Non-directive supportive therapy for depression: A meta-analytic review. *J Affect Disord.* 2024;349:452-461.
31. Cuijpers P, Quero S, Noma H, et al. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. *World Psychiatry.* 2021;20(2):283-293.
32. Kopf-Beck J, Müller CL, Tamm J, et al. Effectiveness of schema therapy versus cognitive behavioral therapy versus supportive therapy for depression in inpatient and day clinic settings: a randomized clinical trial. *Psychother Psychosom.* 2024;93(1):24-35.
33. Seshadri A, Orth SS, Adaji A, et al. Mindfulness-based cognitive therapy, acceptance and commitment therapy, and positive psychotherapy for major depression. *Am J Psychother.* 2021;74(1):4-12.
34. Cuijpers P, Noma H, Karyotaki E, et al. Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: a network meta-analysis. *JAMA Psychiatry.* 2019;76(7):700-707.
35. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. *BMJ.* 1995;310(6974):221-224.
36. McKenzie MS, McFarland BH. Trends in antidepressant overdoses. *Pharmacoepidemiol Drug Saf.* 2007;16(5):513-523.
37. Garcia E, Santos C. Monoamine Oxidase Inhibitor Toxicity: StatPearls Publishing. 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459386/> [Accessed 3 March 2025].
38. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet.* 2018;391(10128):1357-1366.
39. Brown LC, Stanton JD, Bharthi K, et al. Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials. *Clin Pharmacol Ther.* 2022;112(6):1303-1317.

40. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. *BMJ*. 2009;339:b2880.
41. Coupland C, Hill T, Morriss R, et al. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. *BMJ*. 2015;350:h517.
42. Guo T, Xiang YT, Xiao L, et al. Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. *Am J Psychiatry*. 2015;172(10):1004-1013.
43. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am J Psychiatry*. 2006;163(1):28-40.
44. World Health Organization. Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders. Geneva, World Health Organization. 2023.
45. Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust N Z J Psychiatry*. 2021;55(1):7-117.
46. The Best Practice Advocacy Centre New Zealand. The role of medicines in the management of depression in primary care. 2021. Available from: <https://bpac.org.nz/2021/depression.aspx> [Accessed 3 March 2025].
47. Hertfordshire Partnership University NHS Foundation Trust, East and North Hertfordshire Clinical Commissioning Group, Herts Valleys Clinical Commissioning Group. Guidelines on choice and selection of antidepressants for the management of depression. 2018. Available from: <https://www.hpft.nhs.uk/information-and-resources/pharmacy-and-medicines-optimisation/medicines-formulary/bnf-chapter-4-central-nervous-system/3-mental-health-disorders/34-depression/> [Accessed 3 March 2025].
48. Horowitz MA, Framer A, Hengartner MP, et al. Estimating risk of antidepressant withdrawal from a review of published data. *CNS Drugs*. 2023;37(2):143-157.
49. Centre for Effective Practice. Anxiety and Depression. 2023. Available from: <https://tools.cep.health/tool/anxiety-and-depression/#management> [Accessed 3 March 2025].
50. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. *Int J Neuropsychopharmacol*. 2015;19(2):pyv082.
51. Mayo Clinic. Depression Medication Choice - Decision Aid. 2017. Available from: <https://depressiondecisionaid.mayoclinic.org/app/depression> [Accessed 3 March 2025].
52. Quality Use of Medicines Alliance. Medicines comparison table. 2024. Available from: <https://medcast.com.au/qhub/antidepressants-in-older-adults/resources> [Accessed 3 March 2025].
53. Zeiss R, Malejko K, Connemann B, et al. Sexual dysfunction induced by antidepressants – a pharmacovigilance study using data from VigiBase™. *Pharmaceuticals (Basel)*. 2024; 17(7):826.
54. Gheysens T, Van Den Eede F, De Picker L. The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds. *Eur Psychiatry*. 2024;67(1):e20.
55. Hajizadeh A, Howes S, Theodoulou A, et al. Antidepressants for smoking cessation. *Cochrane Database Syst Rev*. 2023; 5(5):CD000031.
56. Ho CS, Zhang MW, Wen HK, et al. Mastering psychiatry - a core textbook for undergraduates (2023 edition): National University of Singapore; 2023. Available from: <https://medicine.nus.edu.sg/psy-med-mastering-psychiatry/> [Accessed 3 March 2025].
57. Singhealth Polyclinics. SHP Clinical Guidebook: Mood and anxiety disorders clinical care path. 2024.
58. Mikkelsen N, Damkier P, Pedersen SA. Serotonin syndrome – a focused review. *Basic Clin Pharmacol Toxicol*. 2023;133(2):124-129.
59. Sansone RA, Sansone LA. Agomelatine: a novel antidepressant. *Innov Clin Neurosci*. 2011;8(11):10-14.

60. Werson AD, Meiser-Stedman R, Laidlaw K. A meta-analysis of CBT efficacy for depression comparing adults and older adults. *J Affect Disord.* 2022;319:189-201.
61. Mallery L, MacLeod T, Allen M, et al. Systematic review and meta-analysis of second-generation antidepressants for the treatment of older adults with depression: questionable benefit and considerations for frailty. *BMC Geriatr.* 2019;19(1):306.
62. Tham A, Jonsson U, Andersson G, et al. Efficacy and tolerability of antidepressants in people aged 65 years or older with major depressive disorder – A systematic review and a meta-analysis. *J Affect Disord.* 2016;205:1-12.
63. Orgeta V, Leung P, del-Pino-Casado R, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. *Cochrane Database Syst Rev.* 2022;4(4):CD009125.
64. Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis. *BMJ.* 2021;372:n532.
65. Dudas R, Malouf R, McCleery J, et al. Antidepressants for treating depression in dementia. *Cochrane Database Syst Rev.* 2018;8(8):CD003944.
66. Lenouvel E, Tobias S, Mühlbauer V, et al. Antidepressants for treating depression among older adults with dementia: a systematic review and meta-analysis. *Psychiatry Res.* 2024;340:116114.
67. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. *Am J Psychiatry.* 2008;165(3):342-351.
68. Ionescu DF, Niciu MJ, Richards EM, et al. Pharmacologic treatment of dimensional anxious depression: a review. *Prim Care Companion CNS Disord.* 2014;16(3).
69. Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. *J Psychiatr Res.* 2008;42(2):134-140.
70. Fava M, Martinez JM, Greist J, et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. *Ann Clin Psychiatry.* 2007;19(3):187-195.
71. Sir A, D'Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. *J Clin Psychiatry.* 2005;66(10):1312-1320.
72. Baldwin DS, Florea I, Jacobsen PL, et al. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. *J Affect Disord.* 2016;206:140-150.
73. Noetel M, Sanders T, Gallardo-Gómez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. *BMJ.* 2024;384:e075847.
74. Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John's wort for major depressive disorder. *Syst Rev.* 2016;5(1):148.
75. Sarris J, Ravindran A, Yatham LN, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. *World J Biol Psychiatry.* 2022;23(6):424-455.
76. Zhichao H, Ching LW, Huijuan L, et al. A network meta-analysis on the effectiveness and safety of acupuncture in treating patients with major depressive disorder. *Sci Rep.* 2021;11(1):10384.
77. Smith CA, Armour M, Lee MS, et al. Acupuncture for depression. *Cochrane Database Syst Rev.* 2018;3(3):CD004046.
78. Aalbers S, Fusar-Poli L, Freeman RE, et al. Music therapy for depression. *Cochrane Database Syst Rev.* 2017;11(11):CD004517.
79. Buechner H, Toparlak SM, Ostinelli EG, et al. Community interventions for anxiety and depression in adults and young people: A systematic review. *Aust N Z J Psychiatry.* 2023;57(9):1223-1242.
80. Barnish MS, Nelson-Horne RV. Group-based active artistic interventions for adults with primary anxiety and depression: a systematic review. *BMJ Open.* 2023;13(6):e069310.

81. Zhu M, Hong RH, Yang T, et al. The efficacy of measurement-based care for depressive disorders: systematic review and meta-analysis of randomised controlled trials. *J Clin Psychiatry*. 2021;82(5):18.
82. Furukawa TA, Cipriani A, Cowen PJ, et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. *Lancet Psychiatry*. 2019;6(7):601-609.
83. Zhou S, Li P, Lyu X, et al. Efficacy and dose-response relationships of antidepressants in the acute treatment of major depressive disorders: a systematic review and network meta-analysis. *Chin Med J*. 2024.
84. Klein T, Breilmann J, Schneider C, et al. Dose-response relationship in cognitive behavioral therapy for depression: A nonlinear metaregression analysis. *J Consult Clin Psychol*. 2024;92(5):296-309.
85. HealthHub. Coping with Diabetes and Depression. 2022. Available from: <https://www.healthhub.sg/live-healthy/coping-with-diabetes-and-depression> [Accessed 4 March 2025].
86. National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management (NICE guideline NG222) – Evidence review [D]: further-line treatment. 2022. Available from: <https://www.nice.org.uk/guidance/ng222> [Accessed 4 March 2025].
87. Dunlop BW, LoParo D, Kinkead B, et al. Benefits of sequentially adding cognitive-behavioral therapy or antidepressant medication for adults with nonremitting depression. *Am J Psychiatry*. 2019;176(4):275-286.
88. Breedvelt JFF, Warren FC, Segal Z, et al. Continuation of antidepressants vs sequential psychological interventions to prevent relapse in depression: an individual participant data meta-analysis. *JAMA Psychiatry*. 2021;78(8):868-875.
89. Buckman JEJ, Underwood A, Clarke K, et al. Risk factors for relapse and recurrence of depression in adults and how they operate: a four-phase systematic review and meta-synthesis. *Clin Psychol Rev*. 2018;64:13-38.
90. DeRubeis RJ, Zajecka J, Shelton RC, et al. Prevention of recurrence after recovery from a major depressive episode with antidepressant medication alone or in combination with cognitive behavioral therapy: phase 2 of a 2-phase randomized clinical trial. *JAMA Psychiatry*. 2020;77(3):237-245.
91. Bansal N, Hudda M, Payne RA, et al. Antidepressant use and risk of adverse outcomes: population-based cohort study. *BJPsych Open*. 2022;8(5):e164.
92. Miidera H, Enomoto M, Kitamura S, et al. Association between the use of antidepressants and the risk of type 2 diabetes: a large, population-based cohort study in Japan. *Diabetes Care*. 2020;43(4):885-893.
93. Gabriel M, Sharma V. Antidepressant discontinuation syndrome. *CMAJ*. 2017;189(21):E747.
94. Chen H, Chua TE, Lee TMY, et al. Consensus statement on Singapore perinatal mental health guidelines on depression and anxiety. *Ann Acad Med Singap*. 2023;52(9):467-475.
95. National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance (NICE guideline CG192). 2020. Available from: <https://www.nice.org.uk/guidance/cg192> [Accessed 4 March 2025].
96. Highet NJ, and the Expert Working Group and Expert Subcommittees. Mental Health Care in the Perinatal Period: Australian Clinical Practice Guideline. Melbourne: Centre of Perinatal Excellence (COPE). 2023.
97. Department of Veterans Affairs and Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of pregnancy. Washington, DC: U.S. Government Printing Office. 2023.
98. Registered Nurses' Association of Ontario. Assessment and Interventions for Perinatal Depression, Second Edition. Toronto (ON): Registered Nurses' Association of Ontario. 2018.
99. Dennis CL, Chung-Lee L. Postpartum depression help-seeking barriers and maternal treatment preferences: a qualitative systematic review. *Birth*. 2006;33(4):323-331.
100. van Ravesteyn LM, Lambregtse-van den Berg MP, Hoogendijk WJG, et al. Interventions to treat mental disorders during pregnancy: a systematic review and multiple treatment meta-analysis. *PLoS One*. 2017;12(3):e0173397.

101. Dennis CL, Hodnett ED. Psychosocial and psychological interventions for treating postpartum depression. *Cochrane Database Syst Rev*. 2007;(4):CD006116.
102. Felker A, Patel R, Kotnis R, Kenyon S, Marian Knight on behalf of MBRRACE-UK. Saving Lives, Improving Mothers' Care Compiled Report - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2020-22. Oxford: National Perinatal Epidemiology Unit, University of Oxford. 2024.
103. Ghimire U, Papabathini SS, Kawuki J, et al. Depression during pregnancy and the risk of low birth weight, preterm birth and intrauterine growth restriction- an updated meta-analysis. *Early Hum Dev*. 2021;152:105243.
104. Slomian J, Honvo G, Emonts P, et al. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. *Women's Health (Lond)*. 2019;15:1745506519844044.
105. Viswanathan M, Middleton JC, Stuebe A, et al. AHRQ comparative effectiveness reviews - maternal, fetal, and child outcomes of mental health treatments in women: a systematic review of perinatal pharmacologic interventions. Rockville (MD): Agency for Healthcare Research and Quality (US). 2021.
106. Suzuki S, Kato M. Deterioration/relapse of depression during pregnancy in Japanese women associated with interruption of antidepressant medications. *J Matern Fetal Neonatal Med*. 2017;30(10):1129-1132.
107. Dragioti E, Solmi M, Favaro A, et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. *JAMA Psychiatry*. 2019;76(12):1241-1255.
108. Kautzky A, Slamanig R, Unger A, et al. Neonatal outcome and adaption after in utero exposure to antidepressants: a systematic review and meta-analysis. *Acta Psychiatr Scand*. 2022;145(1):6-28.
109. Brown JV, Wilson CA, Ayre K, et al. Antidepressant treatment for postnatal depression. *Cochrane Database Syst Rev*. 2021;2(2):CD013560.
110. Smit M, Dolman KM, Honig A. Mirtazapine in pregnancy and lactation – a systematic review. *Eur Neuropsychopharmacol*. 2016;26(1):126-135.
111. The American College of Obstetricians and Gynecologists Committee on Clinical Practice Guidelines – Obstetrics. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 5. *Obstet Gynecol*. 2023;141(6):1262-1288.
112. National Institute of Child Health and Human Development. Drugs and Lactation Database (LactMed®) – Sertraline. Bethesda (MD). 2025. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501191/> [Accessed 4 March 2025].
113. Doukrou M, Segal TY. Fifteen-minute consultation: communicating with young people—how to use HEEADSSS, a psychosocial interview for adolescents. *Arch Dis Child Educ Pract Ed*. 2018;103(1):15-19.
114. Cuijpers P, Karyotaki E, Ciharova M, et al. The effects of psychological treatments of depression in children and adolescents on response, reliable change, and deterioration: a systematic review and meta-analysis. *Eur Child Adolesc Psychiatry*. 2023;32(1):177-192.
115. Dardas LA, Xu H, Franklin MS, et al. Cognitive behavioural therapy and medication for treatment of adolescent depression: a network meta-analysis. *Behav Cogn Psychother*. 2023;51(3):230-245.
116. Hetrick SE, McKenzie JE, Bailey AP, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. *Cochrane Database Syst Rev*. 2021;5(5):CD013674.
117. National Institute for Health and Care Excellence (NICE). Depression in children and young people: identification and management (NICE guideline NG134). 2019. Available from: <https://www.nice.org.uk/guidance/ng134> [Accessed 4 March 2025].
118. van Aswegen T, Samartzi E, Morris L, et al. Effectiveness of family-based therapy for depressive symptoms in children and adolescents: A systematic review and meta-analysis. *Int J Psychol*. 2023;58(6):499-511.
119. Viswanathan M, Kennedy SM, McKeeman J, et al. AHRQ comparative effectiveness reviews - treatment of depression in children and adolescents: a systematic review. Rockville (MD): Agency for Healthcare Research and Quality (US). 2020.

120. Teng T, Zhang Z, Yin B, et al. Effect of antidepressants on functioning and quality of life outcomes in children and adolescents with major depressive disorder: a systematic review and meta-analysis. *Transl Psychiatry*. 2022;12(1):183.